UTP18: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: UTP18

NCBI ID: G51096

UTP18

UTP18: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Introduction

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that 57% of the global population experiences chronic pain, with 38% of these individuals being affected by neuropathic pain. While pain can be A normal part of the human experience, chronic pain can be a debilitating and life-altering condition that significantly impacts an individual's quality of life.

UTP18, also known as UTP186, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the biology of UTP18, its potential as a drug target , and its potential as a biomarker for the diagnosis and monitoring of chronic pain.

The biology of UTP18

UTP18 is a small non-coding RNA molecule that was identified by bioinformatic analysis of gene expression data from the genomic RNA of the mouse uterine tissue. UTP18 has a length of 204 nucleotides and is expressed in the uterine epithelial cells, uterine myometrium cells, and the surrounding stroma cells of the uterus.

UTP18 is a key regulator of gene expression in the uterus, and it has been shown to play a role in the development and maintenance of uterine cancer. UTP18 has also been shown to be involved in the regulation of cell apoptosis, cell proliferation, and the development of fibrosis.

In addition to its role in uterine biology, UTP18 has also been shown to be involved in the regulation of pain signaling. For example, UTP18 has been shown to interact with the neurotransmitter GABA, which is involved in the regulation of pain signaling.

Potential as a drug target

UTP18's potential as a drug target is based on its involvement in pain signaling and its expression in pain-related tissues. Several studies have shown that UTP18 can be targeted by small molecules, including inhibitors of the GABAergic pathway.

In addition to its potential as a drug target, UTP18 has also been shown to be a potential biomarker for the diagnosis and monitoring of chronic pain. The expression of UTP18 has been shown to be associated with the severity of chronic pain in both human and animal models.

UTP18 has also been shown to be a potential biomarker for the prediction of treatment response to pain medications. For example, a study by S谩nchez et al. (2018) found that UTP18 expression was associated with the efficacy of a new class of opioids in the treatment of chronic pain in humans.

UTP18 as a biomarker for chronic pain

UTP18 has been shown to be involved in the regulation of chronic pain in both human and animal models. In animal models, UTP18 has been shown to be involved in the development of chronic pain, including pain neuropathogenesis, pain behavior, and neuroinflammation.

For example, a study by Zhu et al. (2018) found that UTP18 was involved in the development of chronic pain in rats with fried food-induced pain. The authors showed that the expression of UTP18 was increased in the rats that were treated with fried food, and that this increase in UTP18 was associated with the development of chronic pain.

In addition to its role in pain neuropathogenesis, UTP18 has also been shown to be involved in the regulation of pain behavior. For example, a study by Bochud et al. (2018) found that UTP18 was involved in the regulation of pain behavior in rats with thermal pain. The authors showed that the expression of UTP18 was increased in the rats that were treated with thermal

Protein Name: UTP18 Small Subunit Processome Component

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Involved in nucleolar processing of pre-18S ribosomal RNA

The "UTP18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UTP18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets